Washington – Two Americans who received trial shots of a coronavirus vaccine earlier this week had their second follow-ups on Wednesday and were now ready for another shot, the US media reported.
And China said on Wednesday it’s ready to start clinical trials of its own coronavirus vaccine, developed by researchers who worked in Wuhan, the ground zero of the pandemic.
Neal Browning and Jennifer Haller are from a group of 45 healthy individuals who have volunteered for a coronavirus vaccine trial in Washington state. The two were among the first to receive the vaccine.
They will go for a blood draw in a week, will have another draw done the week after that and in about a month, they will receive second shots and go through that process again.
In an interview to CNN, Mr Browning said he was doing this to “make this end as quickly as possible for the rest of the world.”
He said he was “healthy enough to … contribute to (this) research” and hoped that the researchers “find a vaccine sooner than later.”
Ms Haller said she was healthy, had the support of her family and friends and worked for a company that allowed her to work remotely, so she decided to volunteer for this vaccine.
“We all feel so helpless right now,” she told CNN. “I feel blessed that I actually am getting to do something here.”
In Beijing, China’s National Medical Products Administration announced approving tests for the country’s first COVID-19 vaccine, which was created by the Academy of Military Medical Sciences in Wuhan.
The vaccine trial, funded by the National Institute of Allergy and Infectious Diseases, started on Monday and would continue for six weeks.
Follow this link to join our WhatsApp group: Join Now
Be Part of Quality Journalism |
Quality journalism takes a lot of time, money and hard work to produce and despite all the hardships we still do it. Our reporters and editors are working overtime in Kashmir and beyond to cover what you care about, break big stories, and expose injustices that can change lives. Today more people are reading Kashmir Observer than ever, but only a handful are paying while advertising revenues are falling fast. |
| ACT NOW |
| MONTHLY | Rs 100 |  |
| YEARLY | Rs 1000 | |
| LIFETIME | Rs 10000 | |
